Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival

Pharmacological Reports

Volumn 66, Issue 1, 2014, Pages 174-178

  Gestaut, Matthew M ^a   Antoon, James W ^a   Burow, Matthew E ^a   Beckman, Barbara S ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemoresistance; Prostate cancer; Sphingolipids; Sphingosine kinase; Sphingosine kinase 2

Indexed keywords

3 (4 CHLOROPHENYL) ADAMANTANE 1 CARBOXYLIC ACID (PYRIDIN 4 YLMETHYL)AMIDE; ABC 294640; ANDROGEN; ANTIMITOTIC AGENT; CASPASE 9; ENZYME INHIBITOR; KI 67 ANTIGEN; SPHINGOSINE KINASE 2; UNCLASSIFIED DRUG; 3-(4-CHLOROPHENYL)-ADAMANTANE-1-CARBOXYLIC ACID (PYRIDIN-4-YLMETHYL)AMIDE; ADAMANTANE; ANTIANDROGEN; PHOSPHOTRANSFERASE; PYRIDINE DERIVATIVE; SPHINGOSINE KINASE;

ANDROGEN THERAPY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HORMONE RESISTANCE; HUMAN; HUMAN CELL; IC 50; LNCAP CELL LINE; MALE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; PATHOLOGY; PHYSIOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ADAMANTANE; ANDROGEN ANTAGONISTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; KI-67 ANTIGEN; MALE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROSTATIC NEOPLASMS; PYRIDINES;

EID: 84899620852     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2013.08.014     Document Type: Article

References (22)

1. Antoon JW, Meacham WD, Bratton MR, Slaughter EM, Rhodes LV, Ashe HB, et al. Pharmacological inhibition of sphingosine kinase isoforms alters estro-gen receptor signaling in human breast cancer. J Mol Endocrinol 2011;46:205-16
2. Antoon JW, White MD, Driver JL, Burow ME, Beckman BS. Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-a breast cancer. Exp Biol Med (Maywood) 2012;237:832-44
3. Antoon JW, White MD, Slaughter EM, Driver JL, Khalili HS, Elliott S, et al. Targeting NFkB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther 2011;11:678-89
4. Baran Y, Salas A, Senkal C, Gunduz U, Bielawski J, Obeid L, et al. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 2007;282:10922-34 (Pubitemid 47100788)
5. Bassoy EY, Baran Y. Bioactive sphingolipids in docetaxel-induced apoptosis in human prostate cancer cells. Biomed Pharmacother 2012;66:103-10
6. Beljanski V, Knaak C, Smith CD. A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J Pharmacol Exp Ther 2010;333:454-64
7. Beljanski V, Knaak C, Zhuang Y, Smith CD. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest New Drugs 2011;29: 1132-42
8. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999;59:1391-9 (Pubitemid 29160097)
9. Chapman J, Gouazé-Andersson V, Messner M, Flowers M, Karimi R, Kester M, et al. Metabolism of short-chain ceramide by human cancer cells-implica-tions for therapeutic approaches. Biochem Pharmacol 2010;80:308-15
10. Dayon A, Brizuela L, Martin C, Mazerolles C, Pirot N, Doumerc N, et al. Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival. PLoS ONE 2009;4:e8048
11. French K, Zhuang Y, Maines L, Gao P, Wang W, Beljanski V, et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 2010;333:129-39
12. Gao P, Peterson YK, Smith RA, Smith CD. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases. PLoS ONE 2012;7:e44543.
13. Gao P, Smith CD. Ablation of sphingosine kinase-2 inhibits tumor cell prolif-eration and migration. Mol Cancer Res 2011
14. Kageyama Y, Hyochi N, Kihara K, Sugiyama H. The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer. Recent Pat Anticancer Drug Discov 2007;2:203-11 (Pubitemid 350200262)
15. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer 2000;88:3009-14 (Pubitemid 30413184)
16. Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman R, et al. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingo-lipid metabolism. J Biol Chem 2005;280:37118-29 (Pubitemid 41587796)
17. Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, Golzio M, et al. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res 2010;70:8651-61
18. Pchejetski D, Bö hler T, Stebbing J, Waxman J. Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer. Nat Rev Urol 2011;8:569-678
19. Pchejetski D, Doumerc N, Golzio M, Naymark M, Teissié J, Kohama T, et al. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther 2008;7:1836-45
20. Prada P, Juan G, Gonzá lez-Suá rez H, Fernández J, Jimenez I, Amón J, et al. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants. BJU Int 2010;106:32-6
21. Pyne N, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer 2010;10:489-503
22. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-22. (Pubitemid 30054364)